Drug Type Live biotherapeutic products |
Synonyms |
Target- |
Mechanism Bacteria replacements, Gastrointestinal microbiome modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization LISCure Bioscience Co. Ltd.Startup |
Active Organization LISCure Bioscience Co. Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 2 | AU | LISCure Bioscience Co. Ltd.Startup | 04 Jan 2022 |
Rheumatoid Arthritis | Phase 2 | AU | LISCure Bioscience Co. Ltd.Startup | 04 Jan 2022 |
Autoimmune Diseases | Phase 2 | KR | LISCure Bioscience Co. Ltd.Startup | - |